HomeNewsBusinessExclusive | COVID-19: NPPA seeks urgent supply details on gloves, PPEs, kits, and ventilators as hoarding fears rise

Exclusive | COVID-19: NPPA seeks urgent supply details on gloves, PPEs, kits, and ventilators as hoarding fears rise

The drug regulator has also sought details of stock in hand of these items at the retail level –pharmacies, drug and chemist stores, amid fears of hoarding by retailers, producers and even wealthy individuals.

April 02, 2020 / 08:10 IST
Story continues below Advertisement
Representative image
Representative image

India’s drug price regulator, National Pharmaceutical Pricing Authority (NPPA) has sought details from state governments on order volumes and existing stocks of medical devices and personal protective equipment kits (PPEs) to crack down on potential hoarders, artificial shortage and price rise, as it battles to contain the spread of Coronavirus.

NPPA Chairman Shubhra Singh has asked state governments to give details on the availability of PPE, masks (two-ply, three-ply and N95), gloves, testing kits and ventilators, and the production capacity available in each of these states. It has also sought information on the volume of orders that state governments, state-owned companies, and private hospitals have placed for these.

Story continues below Advertisement

The state governments have been asked to share information by April 5. “This may be treated on priority,” the NPPA chairman said in the letter that Moneycontrol has reviewed.

Singh, who has written to the state chief secretaries, has also sought details of current stock in hand at government hospitals, public sector undertakings, cooperatives, and private health service providers.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show